Replies to post #201512 on Biotech Values

[vinmantoo]

GILD: 12 recent in-depth articles synthesized at http://marketstatsanalytics.com/gild_proscons3.html .

What really bugs me is they talk about PRO140 being a possible challenge to GILD's HIV franchise. PRO140 is an monoclonal antibody that binds to the CCR5 receptor and blocks HIV entry. It was developed by PGNX and was the major reason I invested in PGNX a long, long time ago. PGNX sold it off to the small company listed in the article for a small percentage of future sales, and we heard nothing about it for a long time.